Clozapine (Clozaril)

What it treats

Clozapine is approved by the U.S. Food and Drug Administration for treatment-resistant schizophrenia, defined as inadequate response to at least two other antipsychotics tried at adequate dose and duration, and for reducing recurrent suicidal behavior in people with schizophrenia or schizoaffective disorder. It is not a first-line medication. Its role is to help the people for whom other antipsychotics have not been enough.

Getting to clozapine is often a longer road than getting to other antipsychotics, which is a real barrier. Guidelines are clear that it is under-used relative to how well it works in the group it is meant for.

How it works

Clozapine acts on many receptors at once, dopamine (relatively weakly, compared with older antipsychotics), serotonin, histamine, muscarinic, and adrenergic receptors. It is one of the broadest-acting antipsychotics available.

The full reason clozapine works when other antipsychotics have failed is not settled. Its unusually weak D2 blockade may be part of it, along with the balance of other receptor effects. Whatever the exact mechanism, decades of trial and registry data show it is more effective than any other single antipsychotic for treatment-resistant schizophrenia.

Receptor mechanism (detail)

Clozapine is a broad-spectrum antagonist. Its receptor profile includes D1, D2 (relatively weak), D4, 5-HT2A, 5-HT2C, 5-HT6, 5-HT7, H1, muscarinic M1 through M5, α1, and α2. The comparatively weak D2 blockade explains why extrapyramidal side effects and tardive dyskinesia are less common than with older antipsychotics. The strong H1 and 5-HT2C blockade drive weight gain and appetite change. The strong muscarinic blockade drives dry mouth, constipation, and, paradoxically, sialorrhea (drooling), because of a particular effect on salivary receptors. Its unique efficacy in treatment-resistant schizophrenia is not fully explained by the receptor profile alone.

Potency and typical dosing pattern

Ranges are typical framework only, not a prescription for any individual. Clozapine dosing is unlike any other antipsychotic, the titration is slow and essential.

A typical start is 12.5 to 25 mg on day 1, followed by careful upward increases of 25 to 50 mg per day as tolerated, aiming for 300 to 450 mg per day divided over about two weeks. Target serum levels are 350 to 600 ng/mL, and levels are used more actively than with other antipsychotics. Fast titration carries real risks, orthostatic hypotension, severe sedation, and rarely myocarditis, so the slow start is not optional. If more than two days of doses are missed, re-titration from a low dose is usually required.

Safety monitoring

Clozapine has more monitoring than any other psychiatric medication, and the reason is worth understanding rather than resenting: each element is tied to a specific, recognized risk.

ANC (absolute neutrophil count) monitoring

Neutrophils are a type of white blood cell that fights infection. Clozapine can lower them, sometimes severely. Blood tests catch this early, and stopping clozapine reverses it in most cases.

• Baseline ANC must be at least 1.5 × 10⁹/L before starting clozapine. For people with benign ethnic neutropenia or a DARC-null genotype (in which a lower baseline ANC is normal and not a sign of disease), the threshold to start is at least 1.0 × 10⁹/L.
• Weekly ANC for the first 6 months, then every 2 weeks for months 6 through 12, then monthly indefinitely thereafter.
• Discontinue clozapine for ANC below 1.0 × 10⁹/L (below 0.5 × 10⁹/L in benign ethnic neutropenia), with hematology involvement.
• The FDA eliminated the mandatory Clozapine REMS program on February 24, 2025, so lab results no longer need to be entered into a national registry to obtain the medication. ANC monitoring per the prescribing information remains the standard of care, the labs still need to happen, they just don't feed a central registry anymore.

Myocarditis and cardiomyopathy

Inflammation of the heart muscle (myocarditis) is a rare but serious risk, mostly in the first 4 weeks. Standard practice is a baseline and week 4 troponin, CRP, and ECG, plus clinical vigilance during weeks 1 to 4 for tachycardia at rest, fever, chest pain, and shortness of breath. Any of those symptoms during the first month should prompt urgent contact with the prescriber. Cardiomyopathy can develop later and is monitored with ongoing clinical review.

Metabolic monitoring

Clozapine has one of the highest metabolic footprints among antipsychotics, comparable to or greater than olanzapine. Weight and BMI at baseline, weeks 4, 8, and 12, then quarterly. Fasting glucose or HbA1c and a lipid panel at baseline, three months, then at least annually, and more often if changes appear.

Seizure risk

Clozapine lowers the seizure threshold in a dose-related way. Consider an EEG above 600 mg per day or with serum levels above 600 ng/mL, and be cautious in people with other seizure risk factors.

Constipation and ileus

Severe constipation is under-recognized and can progress to bowel obstruction or ileus, which have been fatal. Ask about bowel function at every visit. Scheduled laxatives, not just as-needed ones, are often needed from early on.

Other

Sialorrhea (drooling), tachycardia, orthostatic hypotension, and sedation are common, especially early. Most ease with time or dose adjustment, but they are real and worth naming.

Metformin co-commencement. Aoife Carolan / Schizophrenia Bulletin guideline.

A clinical guideline led by Aoife Carolan strongly recommends co-commencing metformin alongside high-risk antipsychotics like olanzapine or clozapine. This proactive approach helps mitigate severe metabolic side effects, significantly reducing antipsychotic-induced weight gain and improving insulin resistance. The Schizophrenia Bulletin guideline states that when prescribing olanzapine or clozapine, metformin should be initiated immediately to prevent weight gain and cardiometabolic issues.

Typical titration used in the guideline: 500 mg once daily → 500 mg twice daily after one week → 500 mg increments every two weeks as tolerated → up to 1000 mg twice daily by about week six. Contraindicated with eGFR below 30 mL/min/1.73 m²; renal function is checked annually and metformin is held during acute illness or dehydration.

Source: Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193 to 1203.

What to expect

Common side effects

Most people experience some side effects. The common ones include:

• Sedation.
• Sialorrhea (drooling), especially at night.
• Weight gain and increased appetite.
• Constipation.
• Tachycardia (fast heartbeat).
• Orthostatic hypotension (dizziness on standing).
• Dry mouth.

Constipation deserves to be treated as a serious side effect from the start, not brushed off. Sialorrhea can often be helped with practical measures (a towel on the pillow, sugar-free gum during the day) and sometimes with additional medication.

Serious side effects and warnings

Clozapine carries multiple boxed warnings from the FDA. They are worth reading rather than skimming.

Boxed warnings. Severe neutropenia (low white blood cell counts that can raise infection risk); orthostatic hypotension, bradycardia, and syncope (fainting), especially during titration; seizures; myocarditis and cardiomyopathy; and increased mortality in older adults with dementia-related psychosis.

• Severe neutropenia. Managed with the ANC monitoring schedule above.
• Myocarditis and cardiomyopathy. Highest risk in the first four weeks; monitored with baseline and week 4 troponin, CRP, and ECG.
• Seizures. Dose-related; consider EEG at higher doses or serum levels.
• Severe constipation and ileus. Requires active management, not observation.
• Orthostatic hypotension. Managed with slow titration.
• Metabolic effects. Weight gain, hyperglycemia, and hyperlipidemia, monitored as above.
• Neuroleptic malignant syndrome. A rare but serious reaction with fever, muscle stiffness, and confusion, a medical emergency.

Sexual side effects

Sexual side effects can occur with clozapine, though rates tend to be lower than with medications that raise prolactin more. If they occur and are bothersome, that is worth raising with the prescriber. This is not medical advice.

Weight, appetite, and sleep

Weight gain is common and can be substantial, comparable to or greater than with olanzapine. The Carolan guideline recommends co-commencing metformin from the start of clozapine treatment for exactly this reason. Setting up eating and movement routines early, before habits form around the appetite change, makes a meaningful difference.

Sedation is common and often useful for sleep. Doses are often weighted toward the evening for this reason.

Starting and dosing basics

This section is general background, not a dosing instruction for any individual. The right dose is a decision for a prescriber.

Clozapine comes as tablets, orally disintegrating tablets, and an oral suspension. Titration is slow and closely supervised. If more than two days of doses are missed, re-titration from a low dose is usually required, because tolerance to orthostatic and cardiac effects is lost quickly.

Missed doses and interactions

Missed doses matter more with clozapine than with most medications. Missing more than two consecutive days generally means re-titration from a low dose, because side effects that were previously tolerated can return sharply. Any planned interruption should be discussed with the prescriber in advance.

Smoking speeds up how the body clears clozapine, so smokers often need higher doses; if smoking stops abruptly, clozapine levels can rise and cause toxicity. Other medications, some antibiotics, some antidepressants, oral contraceptives, can also change levels. A full medication and supplement list, including over-the-counter items, needs to be shared with the prescriber and pharmacist. Alcohol worsens sedation and orthostasis and is generally best avoided.

Stopping and tapering

Stopping clozapine should be gradual and planned with the prescriber whenever possible. Abrupt discontinuation can cause rapid return of psychotic symptoms, and in some cases cholinergic rebound (nausea, sweating, agitation). Some situations, a severe drop in ANC, myocarditis, require immediate stopping and are managed acutely, not slowly.

Pregnancy and breastfeeding

This is an area where individual circumstances matter and the decision belongs with a clinician. Untreated psychosis carries its own risks during pregnancy, and clozapine also passes into breast milk. Neonatal ANC is monitored after delivery for infants exposed in utero. Anyone who is pregnant, planning a pregnancy, or breastfeeding should talk it through with their prescriber so the specific risks and benefits can be weighed for their situation.

Cost and generic availability

Clozapine has been available as a generic for years and the medication itself is inexpensive. The real cost of clozapine treatment includes lab draws, clinic visits, and sometimes home health support for monitoring, which insurance coverage does not always fully offset. That practical cost is a real part of the treatment plan.

Common questions

Why is clozapine used only after other antipsychotics fail? Because the monitoring and side-effect profile are heavier than for other antipsychotics, guidelines reserve it for people whose symptoms have not responded to at least two other antipsychotics tried at adequate dose and duration. That said, guidelines also say clozapine is under-used, people wait too long to try it, and many who could benefit never get the chance.

Why do I need blood tests so often? Clozapine can lower neutrophils, a type of white blood cell, sometimes severely, and this is caught early through regular ANC checks. Weekly for six months, every two weeks for the next six months, and monthly thereafter is the schedule that has made severe complications rare.

Did the REMS program really go away? Yes. On February 24, 2025, the FDA eliminated the mandatory Clozapine REMS program, which had required prescribers, pharmacies, and patients to be enrolled and required lab results to be entered into a central registry before dispensing. ANC monitoring itself did not go away, it remains the standard of care per the prescribing information. What changed is that the paperwork and registry step is no longer required, which has removed a real barrier to clozapine access.

Should I take metformin with it? For many people started on clozapine, yes. The Carolan guideline recommends co-commencing metformin with high-risk antipsychotics including clozapine to blunt weight gain and metabolic change. Whether that fits your situation is a decision to make with your prescriber.

Questions to ask your prescriber

• What is the ANC monitoring schedule going to look like for me, and where will the labs happen?
• What symptoms in the first four weeks would mean I should call urgently?
• Should we start metformin at the same time?
• How will we manage constipation from the beginning?
• What is our plan if I have to miss doses for any reason?

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes. Guidelines and prescribing information reviewed and current as of June 8, 2026.

• U.S. Food and Drug Administration. Clozapine (Clozaril) prescribing information (DailyMed).
• MedlinePlus, U.S. National Library of Medicine. Clozapine.
• National Institute of Mental Health. Mental health medications.
• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia, 3rd edition.
• National Institute for Health and Care Excellence (NICE). CG178, Psychosis and schizophrenia in adults.
• American Diabetes Association / American Psychiatric Association. Consensus Statement on Antipsychotic Drugs and Obesity and Diabetes.
• Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193 to 1203.
• FDA Drug Safety Communication (February 24, 2025): Clozapine REMS elimination.
• American Association of Psychiatric Pharmacists (AAPP). Clozapine in Practice (2025).